Secondary Logo

Journal Logo

Editorial introductions

Editorial introductions

doi: 10.1097/MOL.0b013e32834345f0
  • Free

Current Opinion in Lipidology was launched in 1990. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of lipidology is divided into six sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Editor and Section Editors for this issue.


Scott M. Grundy

Figure 1
Figure 1

Scott M. Grundy, MD, PhD, is Director of the Center for Human Nutrition, Chairman of the Department of Clinical Nutrition, and Director of the Clinical and Translational Research Center at the University of Texas (UT) Southwestern Medical Center at Dallas, Texas, and Chief of the Metabolic Unit, Veterans Affairs Medical Center, also in Dallas. In recognition of his academic endeavors, he has earned the title of Distinguished Professor of Internal Medicine at the UT Southwestern Medical School in Dallas. Previous academic appointments include the University of California, San Diego; the National Institutes of Health (NIH) Phoenix Clinical Research Unit; the Rockefeller University in New York City; and Baylor College of Medicine in Houston, Texas. Dr Grundy received his medical degree from Baylor College of Medicine and his doctorate from the Rockefeller University.

Dr Grundy's research interests primarily focus on nutrition and cholesterol and lipoprotein metabolism. Notable research achievements include developing methods for measuring cholesterol balance and biliary lipid secretion in humans; identifying the metabolic causes of cholesterol gallstones; defining effects of saturated and unsaturated fats, especially monounsaturated fatty acids, on cholesterol and lipoprotein metabolism; uncovering genetic defects underlying elevated blood cholesterol and other lipid disorders; and identifying metabolic defects of elevated blood cholesterol, high triglycerides, and low HDL (the good cholesterol), and defining mechanisms of action of several lipid-lowering drugs, notably fibrates and HMG CoA reductase inhibitors (statins). Recently, Dr Grundy's research has focused on the metabolic syndrome. Complementing his research endeavors, he writes for the general medical literature, and has published more than 350 original papers and numerous solicited articles and chapters.

Among the many honors bestowed upon him in the course of his career, Dr Grundy received the Award of Merit, the Distinguished Scientist Award, and the Gold Heart Award from the American Heart Association (AHA), the Bristol-Myers Squibb Award for Distinguished Achievement in Nutrition Research, and the American Society for Clinical Nutrition's E. V. McCollum Award. He was also the recipient of the Roger J. Williams Award in Preventive Nutrition and was awarded an honorary degree in medicine from the University of Helsinki in Finland. Additionally, he holds the distinction of having presented the Lydia J. Roberts Memorial Lecture in Chicago in 1988, the AHA George Lyman Duff Lecture, and the AHA Robert I. Levy Lecture.

Dr Grundy has served in various capacities on a number of AHA committees, including chairmanship of the Nutrition Committee, the Council of Arteriosclerosis, Thrombosis, and Vascular Biology, the Council on Nutrition, Physical Activity, and Metabolism, the Task Force on Risk Reduction and Task Force on Cholesterol. He chaired the Adult Treatment Panels II and III of the National Cholesterol Education Program (NCEP) and is a member of the American Society for Clinical Investigation, the American Association of Physicians, and the National Academy of Sciences (Institute of Medicine).

Section Editors

Ronald P. Mensink

Figure 2
Figure 2

Ronald P. Mensink received in 1985 an MSc-degree in human nutrition at the Agricultural University in Wageningen. In 1993 he received an MSc-degree in epidemiology. He received his PhD from the same university in 1990. His thesis dealt with the effects of monounsaturated fatty acids on high-density and low-density lipoprotein cholesterol levels and blood pressure in healthy men and women.

In 1990 he moved to the Department of Human Biology at the Maastricht University, where he has held a Chair in Molecular Nutrition since 2000. He is leader of Research Line 1: ‘The Metabolic Syndrome’ and Chairman of the Department of Human Biology at the School for Nutrition, Toxicology and Metabolism, Maastricht, the Netherlands (NUTRIM).

His primary research interests are the relationships between nutritive and nonnutritive components in the diet, including functional foods, with risk markers for the metabolic syndrome. His experiments are mainly carried out with human volunteers, but also with transgenic animals and cell cultures, and his studies are designed to look not only at effects, but also to unravel the biochemical and molecular mechanisms which underlie these effects.

Paul Nestel

Figure 3
Figure 3

Prof. Nestel is currently on the Senior Faculty of the Baker Heart and Diabetes Institute, Melbourne and Honorary Professor of Medicine in the Faculty of Health Sciences and Medicine, Deakin University, Melbourne. He was formerly chief of the Division of Human Nutrition at the Australian Commonwealth Scientific and Industrial Research Organization (CSIRO) and clinical professor in medicine at Flinders University, Adelaide. He has served on numerous national and international working parties related to establishing policies in nutrition and cardiovascular disease prevention. He received the Order of Australia for research and policy development to prevent heart disease.

He has published over 430 scientific papers dealing with nutrition, cardiovascular disease and its prevention, atherosclerosis and lipid metabolism. In recent years his main research projects dealt with the effects of nutritional interventions on arterial and sympathetic nerve functions in at risk human populations and nutritional aspects related to lipoproteins and the metabolic syndrome.

© 2011 Lippincott Williams & Wilkins, Inc.